Plain-English translation of NCT07202065 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether patients with blood cancers can safely receive a lower dose of intravenous immunoglobulin (IVIg) — an immune protein infusion — compared to the standard higher dose. The study wants to see if the lower dose still protects patients from dangerous bacterial infections while potentially reducing the burden of treatment.
Patients with certain blood cancers have weakened immune systems and need regular infusions of immune proteins to prevent serious infections. Doctors want to know if a lower dose of this medication might work just as well while being easier for patients to manage and potentially reducing costs.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous immunoglobulin infusions once a month (every 4 weeks). Depending on which group you're assigned to, you'll receive either a lower dose or the standard dose. Your doctor will monitor your blood work to ensure the treatment is working well and that you're staying healthy and protected from infections.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Australia